M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy
A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.
At the 2017 Association of Nurses in AIDS Care (ANAC) conference, nurses gathered in Dallas to talk about juggling the medical complexities of HIV infection, managing their patients’ additional comorbid conditions, and providing emotional support.
What’s the best way to begin working in HIV without feeling lost or alone? We asked several community leaders to give advice to people who are newly entering the field.
At the 2017 Association of Nurses in AIDS Care (ANAC) conference, we asked HIV nurses to share a moment in which their unique perspective made a big difference in the care of a particular patient.
Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.
We caught up with speakers and presenters at a major HIV community meeting to learn how HIV care providers can uncover and remove the harm of bias in their work.
This week, a study finds that injectable cabotegravir, an investigational integrase inhibitor, is well tolerated and shows promise as pre-exposure prophylaxis (PrEP).
"Overall, we saw improvements for the whole population, suggesting that the efforts to test [and] diagnose HIV infection sooner, start [antiretroviral] treatment earlier and help patients be retained in care and adherent to their treatment are workin...
Among people starting their first antiretroviral therapy regimen, more advanced HIV disease and black race independently predicted severe weight gain through 96 weeks of follow-up.
Paul Sax, M.D., provides a quick rundown of what he considers the most interesting studies presented at this year's Conference on Retroviruses and Opportunistic Infections.